- Zacks•3 hours ago
Biotech major, Amgen, Inc. (AMGN), announced that its multiple myeloma drug Kyprolis did not meet the primary endpoint in a phase III head-to-head CLARION study with Velcade.
- Investopedia•13 hours ago
The company’s first biosimilar, Amjevita, is now approved for seven common inflammatory ailments and may encroach on AbbVie's $8.4 billion monopoly.
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||170.96 x 100|
|Ask||171.05 x 200|
|Day's Range||170.76 - 172.22|
|52wk Range||135.64 - 176.85|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||17.49|
|Avg Vol (3m)||2,857,300|
|Dividend & Yield||4.00 (2.31%)|